Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ESMO
ESMO
3 Drug Stocks Poised for Gains After Cancer Conference
Investopedia
Sun, 10/6/19 - 12:26 pm
ESMO
cancer
Amgen
Incyte
Bristol-Myers Squibb
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
Xconomy
Tue, 10/1/19 - 10:29 am
ESMO
PARP inhibitors
prostate cancer
KRAS
Seattle Genetics
AstraZeneca
Merck
GSK
Amgen
breast cancer
Roche
Pfizer
Seattle Genetics makes case it can be more than Adcetris
Biopharma Dive
Mon, 09/30/19 - 12:03 pm
Seattle Genetics
Adcetris
clinical trials
ESMO
enfortumab vedotin
Astellas
tucatinib
ESMO: Agios celebrates milestone win for ivosidenib in tough-to-treat bile duct cancer
Fierce Pharma
Mon, 09/30/19 - 10:41 am
Agios
bile duct cancer
Tibsovo
ESMO
ESMO: Merck, Eisai detail Keytruda-Lenvima combo results after triple endometrial cancer OK
Fierce Pharma
Sun, 09/29/19 - 09:37 pm
Merck
Eisai
Keytruda
Lenvima
endometrial cancer
ESMO
ESMO: AstraZeneca eyes payer boost with Tagrisso's latest survival win
Fierce Pharma
Sun, 09/29/19 - 09:29 pm
AstraZeneca
Tagrisso
EGFR lung cancer
ESMO
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Yahoo/Reuters
Sun, 09/29/19 - 11:57 am
GSK
AstraZeneca
ESMO
ovarianc cancer
PARP inhibitors
Lynparza
Zejula
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
Fierce Pharma
Sat, 09/28/19 - 04:49 pm
Roche
Avastin
ovarian cancer
AstraZeneca
Merck
Lynparza
ESMO
Colon cancer proves tougher target for Amgen's KRAS drug
Biopharma Dive
Sat, 09/28/19 - 04:43 pm
Amgen
colon cancer
ESMO
KRAS
ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers
Fierce Biotech
Sat, 09/28/19 - 04:36 pm
Seattle Genetics
Astellas
enfortumab vedotin
bladder cancer
ESMO
urothelial cancer
Updated Erleada Data Shows Reduced Risk of Death in Prostate Cancer Patients
BioSpace
Sat, 09/28/19 - 04:25 pm
Erleada
Janssen
JNJ
ESMO
prostate cancer
Shiny, new and expensive: ESMO studies find new cancer drugs carry higher prices, add little benefit
Fierce Pharma
Fri, 09/27/19 - 10:46 am
cancer
ESMO
drug pricing
oncology
Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress
Pharmaceutical Business Review
Fri, 09/27/19 - 09:34 am
ESMO
Samsung Bioepis
clinical trials
SB8
biosimilars
bevacizumab
non-small cell lung cancer
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
BioSpace
Thu, 09/26/19 - 12:33 pm
GSK
AstraZeneca
PARP inhibitors
ESMO
Lynparza
Zejula
Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus
EP Vantage
Tue, 09/10/19 - 11:49 pm
ESMO
Keytruda
Tecentriq
Merck
Roche
ESMO 2019 preview – PARPs on parade
EP Vantage
Thu, 09/5/19 - 12:06 pm
ESMO
PARP inhibitors
Lynparza
AstraZeneca
ovarian cancer
GSK
Zejula
ESMO18: Novartis PI3K combo therapy boosts survival in subset of breast cancer patients
Fierce Biotech
Sat, 10/20/18 - 11:10 pm
Europe
Novartis
ESMO
AstraZeneca
breast cancer
BYL719
#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage
Endpoints
Mon, 09/11/17 - 09:17 am
ESMO
Eli Lilly
Pfizer
Novartis
abemaciclib
breast cancer
ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals
Fierce Pharma
Mon, 09/11/17 - 09:09 am
ESMO
Merck
Keytruda
bladder cancer
ESMO: AstraZeneca wows with Imfinzi's 11-month survival edge in lung cancer
Fierce Pharma
Sun, 09/10/17 - 11:43 am
ESMO
AstraZeneca
Imfinzi
lung cancer
Pages
« first
‹ previous
1
2
3
4
5
6
next ›
last »